Abstract: The present invention concerns a compound of following formula (1): where: —R1 is H or OH, —R2 is a (C1-C6)alkyl, COOH, COO—((C1-C6)alkyl) or thiazolyl group, —R3 is H or a (C1-C6)alkyl group, and —R4 is: ?a straight-chain or branched, saturated or unsaturated hydrocarbon group having 1 to 8 carbon atoms substituted by one or more groups chosen from among OH and NR5R6, ?—(CH2CH2X1)(CH2CH2X2)a2(CH2CH2X3)a3(CH2CH2X4)a4(CH2CH2X5)a5R7, ?an aryl-(C1-C8)alkyl group substituted by one N or more groups chosen from among OH and NR9R10 groups, or ?a heterocycle-(C1-C8)alkyl group optionally substituted by one or C more groups chosen from among (C1-C6)alkyl, OH and NR12R13 groups, or a pharmaceutically acceptable salt, hydrate or solvate thereof, and its uses in particular for the treatment of cancer, pharmaceutical compositions containing the same and the preparation methods thereof.
Type:
Application
Filed:
May 30, 2019
Publication date:
January 9, 2020
Applicant:
PIERRE FABRE MEDICAMENT
Inventors:
Michel PEREZ, Ian RILATT, Marie LAMOTHE
Abstract: Trilobine and its natural triple-bridged bisbenzylisoquinoline alkaloidal analogues as DNMT inhibitors for use as a drug for the treatment of cancer and neurological diseases and for cell reprogramming, in particular to prime for chemotherapy or immunotherapy.
Type:
Grant
Filed:
October 3, 2016
Date of Patent:
December 31, 2019
Assignees:
PIERRE FABRE MEDICAMENT, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
Inventors:
Yoann Menon, Christophe Long, François Sautel, Paola B. Arimondo
Abstract: The invention relates to compounds of the following general formula (I) in the form of one of the enantiomers thereof or a mixture of the enantiomers thereof, and the pharmaceutically acceptable salts and/or solvates thereof, especially for the use thereof as a medicament, more specifically in cancer treatment. The invention also relates to pharmaceutical compositions containing same and to the methods for the production thereof.
Type:
Grant
Filed:
December 1, 2017
Date of Patent:
December 31, 2019
Assignee:
PIERRE FABRE MEDICAMENT
Inventors:
Frédéric Marion, El Bachir Kaloun, Frédéric Lieby-Muller, Michel Perez, Jean-Philippe Annereau, Laurent Creancier
Abstract: The invention relates to a novel antibody capable of binding specifically to the human c-Met receptor and/or capable of specifically inhibiting the tyrosine kinase activity of said receptor, with an improved antagonistic activity, said antibody comprising a modified hinge region. The invention also relates to a composition comprising such an antibody antagonist to c-Met and its use as a medicament for treating cancer.
Abstract: The present invention relates to an antibody, in particular a monoclonal antibody, capable of binding to IGF-1R, as well as the amino and nucleic acid sequences coding for said antibody. From one aspect, the invention relates to an antibody, or an antigen binding fragment thereof, capable of binding to IGF-1R and, by inducing internalization of IGF-1R, being internalized into the cell. The invention also comprises the use of said antibody as an addressing product or vehicle in conjugation with other anti-cancer compounds such as toxins, radio-elements or drugs, and the use of same for the treatment of certain cancers.
Type:
Application
Filed:
December 18, 2018
Publication date:
October 31, 2019
Applicant:
PIERRE FABRE MEDICAMENT
Inventors:
Liliane GOETSCH, Matthieu Broussas, Charlotte BEAU-LARVOR, Thierry Champion, Alain Robert
Abstract: The present disclosure relates to a novel antibody, in particular a monoclonal antibody, capable of binding to IGF-1R, as well as the amino and nucleic acid sequences coding for said antibody.
Abstract: The present invention relates to compounds of the following formula (I) and pharmaceutically acceptable salts and solvates thereof, their methods of preparation, their use as a drug, notably in the treatment of cancer, and pharmaceutical compositions containing such compounds.
Type:
Grant
Filed:
March 25, 2016
Date of Patent:
October 22, 2019
Assignees:
Centre National de la Recherche Scientifique (CNRS), Pierre Fabre Medicament, Sapienza Universita di Roma
Inventors:
Ludovic Halby, Paola Arimondo, Antonello Mai, Dante Rotili
Abstract: The present invention relates to a pharmaceutical combination comprising: (a) vinflunine or a pharmaceutically acceptable salt thereof, and (b) at least one PD1-inhibitor and/or at least one PD-L1-inhibitor or pharmaceutically acceptable salt thereof. Such a pharmaceutical combination is useful as a drug, notably in the treatment of a proliferative disease, such as cancer.
Type:
Application
Filed:
July 6, 2017
Publication date:
October 10, 2019
Applicant:
PIERRE FABRE MEDICAMENT
Inventors:
Anna KRUCZYNSKI, Isabelle VANDENBERGHE, Pierre FERRE
Abstract: The present disclosure relates generally to anti-C10orf54 antibodies, including antibody-drug conjugates comprising the antibodies, and methods of their use.
Type:
Grant
Filed:
August 2, 2018
Date of Patent:
September 24, 2019
Assignee:
PIERRE FABRE MEDICAMENT
Inventors:
John Lippincott, Edward Thein Htun Van Der Horst, Sun Young Kim, Leonard G. Presta
Abstract: The present disclosure relates generally to anti-C10orf54 antibodies, including antibody-drug conjugates comprising the antibodies, and methods of their use.
Type:
Grant
Filed:
August 2, 2018
Date of Patent:
September 17, 2019
Assignee:
PIERRE FABRE MEDICAMENT
Inventors:
John Lippincott, Edward Thein Htun Van Der Horst, Sun Young Kim, Leonard G. Presta
Abstract: The present invention relates to an antibody-drug-conjugate. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to a Target, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.
Type:
Application
Filed:
April 16, 2019
Publication date:
September 5, 2019
Applicant:
PIERRE FABRE MEDICAMENT
Inventors:
Ian RILATT, Michel PEREZ, Liliane GOETSCH, Matthieu BROUSSAS, Charlotte BEAU-LARVOR, Jean-François HAEUW, Marie LAMOTHE
Abstract: The present invention relates to a compound with the following formula (I): (I) or a salt and/or a pharmaceutically acceptable solvate thereof, in particular for use as a drug, in particular in the treatment of cancer, as well as to the pharmaceutical compositions that contain same and to the methods for preparing same.
Type:
Grant
Filed:
September 2, 2015
Date of Patent:
June 18, 2019
Assignee:
PIERRE FABRE MEDICAMENT
Inventors:
El Bachir Kaloun, Serge Grisoni, Anna Kruczynski, Philippe Schmitt
Abstract: The present invention relates to an antibody-drug-conjugate. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to a Target, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.
Type:
Grant
Filed:
April 27, 2015
Date of Patent:
June 11, 2019
Assignee:
PIERRE FABRE MEDICAMENT
Inventors:
Ian Rilatt, Michel Perez, Liliane Goetsch, Matthieu Broussas, Charlotte Beau-Larvor, Jean-Francois Haeuw, Marie Lamothe
Abstract: The present invention relates to a method of treating schizophrenia in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a selective D3 antagonist, wherein said subject has at least one negative symptom (NS) among the following core negative symptoms in PANSS: Blunted Affect (N1), Emotional Withdrawal (N2), Poor Rapport (N3), Passive withdrawal (N4), and Lack of Spontaneity (N6); with moderate or higher severity. Methods for improving the probability of success and/or the effect of a treatment of schizophrenia in a subject in need thereof are also described.
Abstract: The present invention relates to the use of PAR1 antagonists, in particular of vorapaxar, of atopaxar and of 3-(2-chlorophenyl)-1-[4-(4-fluorobenzyl)piperazin-1-yl]propenone, or a pharmaceutically acceptable salt thereof, for preventing and/or treating pelvi-perineal functional pathological conditions, and more particularly painful bladder syndrome.
Type:
Grant
Filed:
April 25, 2018
Date of Patent:
April 23, 2019
Assignee:
Pierre Fabre Medicament
Inventors:
Bruno Le Grand, Didier Junquero, Nicolas Monjotin
Abstract: The present invention relates to a transdermal device including porous microparticles capable of containing an active principle, in particular nicotine, and to the use thereof as a drug, in particular for tobacco cessation. The present invention further relates to a method for preparing a transdermal device including porous microparticles filled with an active principle.
Type:
Application
Filed:
November 16, 2018
Publication date:
March 21, 2019
Applicant:
PIERRE FABRE MEDICAMENT
Inventors:
Isabel RIBEIRO DOS SANTOS, Michel SOURNAC
Abstract: The present invention relates to a new method for capturing and analysing antibody-drug conjugates (ADCs) in biological samples, such as e.g., serum. Methods for analysing the structure of an antibody-drug conjugate (ADC) in a biological sample and methods for assessing the stability of an ADC are also provided.
Abstract: The invention concerns a compound of the following formula (I) or a pharmaceutically acceptable salt or solvate thereof as well as a pharmaceutical composition containing such a compound, and the use of such a compound as a drug, notably as a DNMT inhibitor, in particular in the treatment of cancer.
Type:
Application
Filed:
October 3, 2016
Publication date:
February 28, 2019
Applicants:
PIERRE FABRE MEDICAMENT, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
Inventors:
Ludovic HALBY, Yoann MENON, El Bachir KALOUN, Christophe LONG, Paola B. ARIMONDO
Abstract: The present disclosure relates to IGF-IR (insulin like growth factor receptor-1) antibodies characterized by CDR sequences a, to be used in detection methods of IGF-IR expressing tumoral cells.
Abstract: The present invention relates to an antibody, in particular a monoclonal antibody, capable of binding to IGF-1R, as well as the amino and nucleic acid sequences coding for said antibody. From one aspect, the invention relates to an antibody, or an antigen binding fragment thereof, capable of binding to IGF-1R and, by inducing internalization of IGF-1R, being internalized into the cell. The invention also comprises the use of said antibody as an addressing product or vehicle in conjugation with other anti-cancer compounds such as toxins, radio-elements or drugs, and the use of same for the treatment of certain cancers.
Type:
Grant
Filed:
April 27, 2015
Date of Patent:
February 12, 2019
Assignee:
PIERRE FABRE MEDICAMENT
Inventors:
Liliane Goetsch, Matthieu Broussas, Charlotte Beau-Larvor, Thierry Champion, Alain Robert